OCTS USA 2021 | Kisaco Research

OCTS USA 2021

Revolutionizing patient outcomes in cancer therapies

Download 2021 agenda preview

OCTS USA 2021

Boston, USA
16-18 November, 2021

“The event was very interesting and well organised. I liked the mixture of scientific talks with updates on current developments alongside a more practical ‘logistical and regulatory’ issues one encountered in the daily life of delivering these treatments to patients in clinical trial.”

UCL

“Optimal meeting size to enable communication with all the participants. Ideal for networking.”

Celyad

Why Attend

The world shut down in 2020 as the pandemic had a global impact on trade and development, but the onco cell therapy industry remained resilient in the face of all of this. In spite of 69% of industry claiming that their biggest challenges in 2020 was meeting their projected timelines for their pipes, the race for bringing the first BCMA targeting CAR-T to the market is reaching a climax and next-generation cell therapies are at the front of mind for those in both industry and research.

Significant break throughs in GvHD for allogeneic treatments and in the use of alternative cell therapies mean that onco cell therapies are embedding themselves as the 5th pillar of oncology. New combination studies and manufacturing capabilities are showing even more promise for this sector, but with current treatments still having high costs of use and as there are limited patient pools, there are still challenges in both clinical and commercial use of these therapies.

The Onco Cell Therapy Summit (OCTS), November 16 - 18, Boston USA, brings the industry together to share novel research, manufacturing techniques, and regulatory best practice. Each session of OCTS 2021 is dedicated to the process of translating R&D into commercially viable oncological therapies.

We’ve worked with industry partners to ensure that OCTS 2021 is dedicated to the effective translation and commercialization of research into safe and efficacious therapies and address these challenges.

Meet our 2021 Industry- Leading Speakers

 

Dr. Kristen Hege

SVP of Early Clinical Development – Hematology/ Oncology
Bristol Meyers Squibb

Dr. Kristen Hege

SVP of Early Clinical Development – Hematology/ Oncology
Bristol Meyers Squibb

Dr. Kristen Hege

SVP of Early Clinical Development – Hematology/ Oncology
Bristol Meyers Squibb
 

Frank Fan

Co-Founder & CSO
Legend Biotech

Frank Fan

Co-Founder & CSO
Legend Biotech

Frank Fan

Co-Founder & CSO
Legend Biotech
 

Paul Rennert

President and CSO
Aleta Biotherapeutics

Paul Rennert

President and CSO
Aleta Biotherapeutics

Paul Rennert

President and CSO
Aleta Biotherapeutics
 

Tony Ho

Executive Vice President – Head of Research and Development
CRISPR Therapeutics

Tony Ho

Executive Vice President – Head of Research and Development
CRISPR Therapeutics

Tony Ho

Executive Vice President – Head of Research and Development
CRISPR Therapeutics
 

Bruno Figueroa

Global Head of Genomic Medicine Unit CMC
Sanofi

Bruno Figueroa

Global Head of Genomic Medicine Unit CMC
Sanofi

Bruno Figueroa

Global Head of Genomic Medicine Unit CMC
Sanofi
 

Simon Bornschein

Founder & CEO
coding.bio

Simon Bornschein

Founder & CEO
coding.bio

Simon Bornschein

Founder & CEO
coding.bio
 

Dr. Maria Fardis

President and Chief Executive Officer
Lovance Biotherapeutics

Dr. Maria Fardis joined Iovance Biotherapeutics as President and Chief Executive Officer and was appointed to the Board of Directors in 2016. Since joining, the Company has been transformed from an early-stage development company to a company with multiple late-stage programs involving lifileucel and LN-145 for treatment of multiple solid tumors. Dr.

Dr. Maria Fardis

President and Chief Executive Officer
Lovance Biotherapeutics

Dr. Maria Fardis

President and Chief Executive Officer
Lovance Biotherapeutics

Dr. Maria Fardis joined Iovance Biotherapeutics as President and Chief Executive Officer and was appointed to the Board of Directors in 2016. Since joining, the Company has been transformed from an early-stage development company to a company with multiple late-stage programs involving lifileucel and LN-145 for treatment of multiple solid tumors. Dr. Fardis served as the Chief Operating Officer of Acerta Pharma B.V., a clinical-stage biopharmaceutical company, from January 2015 to March 2016, where she worked on the development of Calquence® until the company’s acquisition by AstraZeneca. From 2011 to 2014, she worked at Pharmacyclics, Inc., where she was a key contributor in the creation of a broad clinical program leading to global approvals for Imbruvica® in multiple hematologic malignancies, and where she served as Chief of Oncology Operations and Alliances. Prior to joining Pharmacyclics, from August 2001 to April 2011, Dr. Fardis held increasingly senior positions in Medicinal Chemistry and the project and portfolio management department at Gilead Sciences, Inc., where she was involved with multiple therapeutic areas including antivirals, oncology, and cardiovascular therapeutics and worked on the development and life cycle management of Letairis®. Dr. Fardis received her Ph.D. in Organic Chemistry from the University of California, Berkeley and her B.S. summa cum laude, in chemistry from the University of Illinois, Urbana-Champaign. Dr. Fardis holds an M.B.A., with highest honors, from Golden Gate University.

 

Pascal Touchon

CEO
Atara Biotherapeutics

Pascal Touchon

CEO
Atara Biotherapeutics

Pascal Touchon

CEO
Atara Biotherapeutics
 

Dr. Matthew Spear

Chief Medical Officer
Poseida Therapeutics

Dr. Matthew Spear

Chief Medical Officer
Poseida Therapeutics

Dr. Matthew Spear

Chief Medical Officer
Poseida Therapeutics
 

Paul Lammers

President & CEO
Triumvira Immunologics

Paul Lammers

President & CEO
Triumvira Immunologics

Paul Lammers

President & CEO
Triumvira Immunologics
 

James Trager

Chief Scientific Officer
Nkarta

James Trager

Chief Scientific Officer
Nkarta

James Trager

Chief Scientific Officer
Nkarta
 

Peggy Sotiropoulou

Head of R&D
Celyad Oncology

Peggy Sotiropoulou

Head of R&D
Celyad Oncology

Peggy Sotiropoulou

Head of R&D
Celyad Oncology
 

Robert Hofmeister

Chief Scientific Officer
TCR2

Robert Hofmeister

Chief Scientific Officer
TCR2

Robert Hofmeister

Chief Scientific Officer
TCR2
 

Gary Lee

CSO
Senti Bio

Gary Lee

CSO
Senti Bio

Gary Lee

CSO
Senti Bio
 

Travis Young

VP Biologics
Calibr

Travis Young

VP Biologics
Calibr

Travis Young

VP Biologics
Calibr
 

Dan Shelly

VP of Development
Prescient Therapeutics

Dan Shelly

VP of Development
Prescient Therapeutics

Dan Shelly

VP of Development
Prescient Therapeutics
 

Alice Brown

VP Research
GammaDelta Therapeutics

Alice Brown

VP Research
GammaDelta Therapeutics

Alice Brown

VP Research
GammaDelta Therapeutics
 

Hanspeter Gerber

CSO
3T Biosciences

Hanspeter Gerber

CSO
3T Biosciences

Hanspeter Gerber

CSO
3T Biosciences
 

Alan Trounson

CEO & President
Cartherics

Alan Trounson

CEO & President
Cartherics

Alan Trounson

CEO & President
Cartherics
 

Roman Yelensky

EVP & CTO
Gritstone Oncology

Roman Yelensky

EVP & CTO
Gritstone Oncology

Roman Yelensky

EVP & CTO
Gritstone Oncology
 

John Rossi

Senior Director
Kite Pharma

John Rossi

Senior Director
Kite Pharma

John Rossi

Senior Director
Kite Pharma
 

Adrian Bot

VP Translational Medicine
Kite Pharma

Adrian Bot

VP Translational Medicine
Kite Pharma

Adrian Bot

VP Translational Medicine
Kite Pharma
 

Dolores Schendel

CEO & CSO
Medigene

Dolores Schendel

CEO & CSO
Medigene

Dolores Schendel

CEO & CSO
Medigene
 

Kristina Carroll

Process Engineer, Process Development Group
Precision Biosciences

Kristina is a Process Engineer and founding member of the Cell Therapy Development team at Precision BioSciences, focused on the development of best-in-class manufacturing methods for allogeneic CAR T therapies.  As an integral part of the CMC team, Kristina led in the development of the large-scale manufacturing process, cold chain logistics for the cryopreserved drug product, and clinical administration protocols.  Prior to joining Precision BioSciences, Kristina worked as a Systems Engineer at Terumo BCT, focusing on upstream and downstream cell processing systems.  She has earned her Ma

Kristina Carroll

Process Engineer, Process Development Group
Precision Biosciences

Kristina Carroll

Process Engineer, Process Development Group
Precision Biosciences

Kristina is a Process Engineer and founding member of the Cell Therapy Development team at Precision BioSciences, focused on the development of best-in-class manufacturing methods for allogeneic CAR T therapies.  As an integral part of the CMC team, Kristina led in the development of the large-scale manufacturing process, cold chain logistics for the cryopreserved drug product, and clinical administration protocols.  Prior to joining Precision BioSciences, Kristina worked as a Systems Engineer at Terumo BCT, focusing on upstream and downstream cell processing systems.  She has earned her Master’s degree in Biomedical Engineering from Rutgers University and Bachelor’s degree in Chemical and Biological Engineering at the University of Colorado at Boulder. When not at Precision, Kristina can be found running nearby trails with her husband and dogs, camping, or creating a disaster in the kitchen.

 

Blake Aftab

VP Preclinical and Translational Sciences
Atara Biotherapeutics

Blake Aftab

VP Preclinical and Translational Sciences
Atara Biotherapeutics

Blake Aftab

VP Preclinical and Translational Sciences
Atara Biotherapeutics
 

Steven Kanner

CSO
Caribou Biosciences

Steven Kanner

CSO
Caribou Biosciences

Steven Kanner

CSO
Caribou Biosciences
 

Donna Rill

Chief Technology Officer
Triumvira Immunologics

Donna Rill

Chief Technology Officer
Triumvira Immunologics

Donna Rill

Chief Technology Officer
Triumvira Immunologics
 

Krishnan Viswanadhan

SVP – Global Cell Therapy Franchise Lead

Krishnan Viswanadhan

SVP – Global Cell Therapy Franchise Lead

Krishnan Viswanadhan

SVP – Global Cell Therapy Franchise Lead
 

Dr. Avery Posey

Department of Pathology and Laboratory Medicine
University of Pennsyvania

Dr. Avery Posey

Department of Pathology and Laboratory Medicine
University of Pennsyvania

Dr. Avery Posey

Department of Pathology and Laboratory Medicine
University of Pennsyvania
 

Frank Thielmann

Director of Operational Excellence
Takeda

Frank Thielmann

Director of Operational Excellence
Takeda

Frank Thielmann

Director of Operational Excellence
Takeda
 

Steven Feldman

Director, Manufacturing and Process Development
Stanford Center for Cancer Cell Therapy

Dr. Steven A. Feldman was a Staff Scientist and Director of the Vector Production Facility at Surgery Branch, NCI for the past twelve years.  Dr. Feldman’s group was responsible for the development, characterization, and manufacturing of the viral vectors used in gene therapy clinical trials at the Surgery Branch.  Recently, Dr. Feldman joined the Stanford Center for Cancer Cell Therapy as Director of Manufacturing and Process Science where he will take a lead role in the development and manufacture of viral vectors and novel cell therapies for the treatment of cancer.

Steven Feldman

Director, Manufacturing and Process Development
Stanford Center for Cancer Cell Therapy

Steven Feldman

Director, Manufacturing and Process Development
Stanford Center for Cancer Cell Therapy

Dr. Steven A. Feldman was a Staff Scientist and Director of the Vector Production Facility at Surgery Branch, NCI for the past twelve years.  Dr. Feldman’s group was responsible for the development, characterization, and manufacturing of the viral vectors used in gene therapy clinical trials at the Surgery Branch.  Recently, Dr. Feldman joined the Stanford Center for Cancer Cell Therapy as Director of Manufacturing and Process Science where he will take a lead role in the development and manufacture of viral vectors and novel cell therapies for the treatment of cancer.

 

Emilie Gauthy

R&D CMC and process development
Celyad Oncology

Emilie Gauthy

R&D CMC and process development
Celyad Oncology

Emilie Gauthy

R&D CMC and process development
Celyad Oncology
 

Nick Huntington

Co-Founder and CSO
oNKo Innate

Nick Huntington

Co-Founder and CSO
oNKo Innate

Nick Huntington

Co-Founder and CSO
oNKo Innate
 

Knut Niss

Chief Technology Officer
Mustang Bio

Dr. Niss has served as Chief Technology Officer since March 2018. Dr. Niss joined Mustang in March 2017 as Vice President of Operations, where he initiated and oversees the establishment of Mustang’s cell therapy manufacturing facility. Prior to Mustang, Dr. Niss was Cell Therapy Asset Leader at Biogen, where he oversaw CMC-related activities for gene-edited hematopoietic stem cell and lentiviral gene therapy programs for sickle cell disease and hemophilia, respectively. Earlier in his career, Dr.

Knut Niss

Chief Technology Officer
Mustang Bio

Knut Niss

Chief Technology Officer
Mustang Bio

Dr. Niss has served as Chief Technology Officer since March 2018. Dr. Niss joined Mustang in March 2017 as Vice President of Operations, where he initiated and oversees the establishment of Mustang’s cell therapy manufacturing facility. Prior to Mustang, Dr. Niss was Cell Therapy Asset Leader at Biogen, where he oversaw CMC-related activities for gene-edited hematopoietic stem cell and lentiviral gene therapy programs for sickle cell disease and hemophilia, respectively. Earlier in his career, Dr. Niss was Senior Technical Project Leader at Novartis’ cell therapy manufacturing facility in Morris Plains, New Jersey, where he directed the transfer and implementation of the CTL019 process from Penn to Novartis. He also served as Senior R&D Program Manager at EMD Millipore, where he established processes for the large-scale expansion of adult and pluripotent stem cells. Dr. Niss began his career in senior research positions in Pfizer’s Regenerative Medicine and Immunology groups. He holds a Ph.D. in molecular biology from Humboldt University of Berlin, and an M.S. in microbiology from the University of Göttingen in Germany. Dr. Niss completed his postdoctoral research at Boston Children’s Hospital and the Dana-Farber Cancer Institute.

 

 

John Tomtishen

Director of Manufacturing, Technical Operations
Legend Biotech

John Tomtishen

Director of Manufacturing, Technical Operations
Legend Biotech

John Tomtishen

Director of Manufacturing, Technical Operations
Legend Biotech
 

Anthony Colenberg

Senior Director of Quality
Adicet Bio

Anthony Colenberg

Senior Director of Quality
Adicet Bio

Anthony Colenberg

Senior Director of Quality
Adicet Bio
 

Chris Heery

CMO
Precision Bioscience

Chris Heery

CMO
Precision Bioscience

Chris Heery

CMO
Precision Bioscience
 

Jason Litten

CMO
Artiva

Jason Litten

CMO
Artiva

Jason Litten

CMO
Artiva
 

Tatiana Novobrantseva

Co-Founder & CSO
Verseau Therapeutics

Tatiana Novobrantseva

Co-Founder & CSO
Verseau Therapeutics

Tatiana Novobrantseva

Co-Founder & CSO
Verseau Therapeutics
 

Kipp Weiskopf

Whitehead Fellow
Whitehead Institute – MIT

Kipp Weiskopf

Whitehead Fellow
Whitehead Institute – MIT

Kipp Weiskopf

Whitehead Fellow
Whitehead Institute – MIT
 

Judith Varner

Professor - Pathology
UCSD

Judith Varner

Professor - Pathology
UCSD

Judith Varner

Professor - Pathology
UCSD
 

Nicholas Poirier

Chief Scientific Officer
OSE Immunotherapies

Nicholas Poirier

Chief Scientific Officer
OSE Immunotherapies

Nicholas Poirier

Chief Scientific Officer
OSE Immunotherapies
 

Yaron Pereg

CEO
Kahr Medical

Yaron Pereg

CEO
Kahr Medical

Yaron Pereg

CEO
Kahr Medical
 

David Cheresh

Distinguished Professor and founder
Alpha Beta Therapeutics

David Cheresh

Distinguished Professor and founder
Alpha Beta Therapeutics

David Cheresh

Distinguished Professor and founder
Alpha Beta Therapeutics
 

Nico Lachmann

Principle Investigator
Hannover Medical School

Nico Lachmann

Principle Investigator
Hannover Medical School

Nico Lachmann

Principle Investigator
Hannover Medical School
 

Michael Klichinsky

Co-Founder & VP Discovery Research
Carisma Therapeutics

Michael Klichinsky

Co-Founder & VP Discovery Research
Carisma Therapeutics

Michael Klichinsky

Co-Founder & VP Discovery Research
Carisma Therapeutics
 

Ashish Kulkarni

Assistant Professor – Department of Chemical Engineering
University of Massachusetts Amherst

Ashish Kulkarni

Assistant Professor – Department of Chemical Engineering
University of Massachusetts Amherst

Ashish Kulkarni

Assistant Professor – Department of Chemical Engineering
University of Massachusetts Amherst
 

Sandro Matosevic

Assistant Professor
Purdue University

Sandro Matosevic

Assistant Professor
Purdue University

Sandro Matosevic

Assistant Professor
Purdue University
 

Eric Von Hofe

CEO, President, Director of Biotechnology
AffyImmune Therapeutics

Eric Von Hofe

CEO, President, Director of Biotechnology
AffyImmune Therapeutics

Eric Von Hofe

CEO, President, Director of Biotechnology
AffyImmune Therapeutics
 

Charles Mooney

Vice President
Oklahoma Blood Institute

Charles Mooney

Vice President
Oklahoma Blood Institute

Charles Mooney

Vice President
Oklahoma Blood Institute
 

Albert Ribickas

BMT/QC Laboratories Manager – Cell Therapies Facility
Moffitt Cancer Center

Albert Ribickas

BMT/QC Laboratories Manager – Cell Therapies Facility
Moffitt Cancer Center

Albert Ribickas

BMT/QC Laboratories Manager – Cell Therapies Facility
Moffitt Cancer Center
 

Bob Valamehr, PhD MBA,

Chief Research & Development Officer
Fate Therapeutics Inc

Bob Valamehr, PhD MBA,

Chief Research & Development Officer
Fate Therapeutics Inc

Bob Valamehr, PhD MBA,

Chief Research & Development Officer
Fate Therapeutics Inc
 

Daniel Getts

CEO
Myeloid Tx

Daniel Getts

CEO
Myeloid Tx

Daniel Getts

CEO
Myeloid Tx
 

Dean Lee

Director of Cellular Therapy
National Children’s Hospital

Dean Lee

Director of Cellular Therapy
National Children’s Hospital

Dean Lee

Director of Cellular Therapy
National Children’s Hospital
 

Dr Meghan F. Hogan

Ph.D – Scientist
NanoString Technologies

Dr Meghan F. Hogan

Ph.D – Scientist
NanoString Technologies

Dr Meghan F. Hogan

Ph.D – Scientist
NanoString Technologies
 

Frederick Locke Vice

Chair & Program Co-Leader
Moffitt Cancer Center

Frederick Locke Vice

Chair & Program Co-Leader
Moffitt Cancer Center

Frederick Locke Vice

Chair & Program Co-Leader
Moffitt Cancer Center
 

Lawrence Lamb

EVP & Chief Scientific Officer
IN8bio

Lawrence Lamb

EVP & Chief Scientific Officer
IN8bio

Lawrence Lamb

EVP & Chief Scientific Officer
IN8bio
 

Minna Montgomery

Senior Director – Business Development and Client Management
American Red Cross

Minna Montgomery

Senior Director – Business Development and Client Management
American Red Cross

Minna Montgomery

Senior Director – Business Development and Client Management
American Red Cross
 

Moa Fransson

CEO
Genagon Therapeutics

Moa Fransson

CEO
Genagon Therapeutics

Moa Fransson

CEO
Genagon Therapeutics
 

Neehar Bhatia

Director, Process Development and Manufacturing
Stanford Laboratory for Cell and Gene Medicine

Neehar Bhatia, Ph.D. is Associate Director of Process Development and Manufacturing at Laboratory of Cell and Gene Medicine (LCGM), Stanford University. Dr. Bhatia received a Ph.D. in Biochemistry from the Central Drug Research Institute, India. Dr. Bhatia is responsible for development and manufacturing of cGMP compliant cell and gene therapy products at LCGM. Dr. Bhatia oversees manufacturing for multiple projects such as CD19/CD22 bi-specific CAR-T and other T cell based therapies, CD34 HSPC transplant and manufacturing of AAV6 for gene correction in HSPC. Dr.

Neehar Bhatia

Director, Process Development and Manufacturing
Stanford Laboratory for Cell and Gene Medicine

Neehar Bhatia

Director, Process Development and Manufacturing
Stanford Laboratory for Cell and Gene Medicine

Neehar Bhatia, Ph.D. is Associate Director of Process Development and Manufacturing at Laboratory of Cell and Gene Medicine (LCGM), Stanford University. Dr. Bhatia received a Ph.D. in Biochemistry from the Central Drug Research Institute, India. Dr. Bhatia is responsible for development and manufacturing of cGMP compliant cell and gene therapy products at LCGM. Dr. Bhatia oversees manufacturing for multiple projects such as CD19/CD22 bi-specific CAR-T and other T cell based therapies, CD34 HSPC transplant and manufacturing of AAV6 for gene correction in HSPC. Dr. Bhatia has lead multiple projects which include banking  of ESCs, iPSCs, MSCs and iPSC derived differentiated cells, development of GMP process for translational projects and manufacturing cell therapies for Phase I/II clinical trials. Dr. Bhatia has also lead efforts in quest for serum-free chemically defined culture medium for MSCs and development of platform technology for AAV production. Dr. Bhatia’s focus is on development of cGMP compliant manufacturing process for “bench to bedside” cell and gene therapies.

 

Rafael Amado

CMO
Allogene

Rafael Amado

CMO
Allogene

Rafael Amado

CMO
Allogene
 

Sheng Lin-Gibson

Chief of the Biosystems and Biomaterials Division
NIST

Sheng Lin-Gibson

Chief of the Biosystems and Biomaterials Division
NIST

Sheng Lin-Gibson

Chief of the Biosystems and Biomaterials Division
NIST
 

William Shingler

Senior Director, Patient and Cell Management
Autolus

William Shingler

Senior Director, Patient and Cell Management
Autolus

William Shingler

Senior Director, Patient and Cell Management
Autolus

Sponsors

Platinum Partner

Gold Partner

Event Partner

Media Partners

PARTNER WITH US

Based on your objectives, we can create bespoke packages designed specifically for you. From presenting your expertize on the main stage to hosting the infamous CAR-T Party. You can partner with us showcase your brand and make valuable new connections. Opportunities predominantly lie in 3 main categories: Thought Leadership, Branding & Networking. Contact Take a look at the Sponsorship Prospectus for more details, or discuss your objectives with Nathan Edwards, Head of Commercial Partnerships; [email protected].

Interested in a media partnership?
We'd love to hear from you and how we can support one another to connect with the industry. Contact Stephanie Wright, Head of Marketing; [email protected] 

Sending Your Team? Group Discounts Available!

Applicable for Primary Market, Service Provider and Industry Rates Only. Not available for Academic or ‘Start-Up’ rates

Book a Team of 3+ - Save an Additional 10% Off
Book a Team of 5+ - Save an Additional 15% Off

If you would like to register a team of 3 or more, please email [email protected] for your discount coupon code before registering. PLEASE NOTE: Discounts cannot be combined with Early Bird Pricing or any other discount or offer. If you have any questions about your registration, please call us on +44 (0)20 3696 2920

We accept the following cards through Stripe:

Ticket price will increase in

Thursday, September 17, 2020 to Friday, August 20, 2021
Tier 1 - Academics/ Biotechs
$999
Super early bird price until August 20,2021. Standard pricing $1599
Academic & Small Biotech under $5m with active cell therapy pipeline
2 day conference pass
Networking opportunities
Refreshments, breakfast & lunch
Wednesday, June 9, 2021 to Friday, August 20, 2021
Tier 2 - Pharmaceutical Companies
$1499
Super early bird price until August 20, 2021. Standard pricing $2499
To increase your brand presence, contact Nathan Edwards [email protected]
2 day conference pass
Networking opportunities
Refreshments, breakfast & lunch
Wednesday, June 9, 2021 to Friday, August 20, 2021
Tier 3 - Service Providers
$2499
Super early bird price until August 20, 2021. Standard pricing $3499
To increase your brand presence, contact Nathan Edwards [email protected]
2 day conference pass
Networking opportunities
Refreshments, breakfast & lunch
Preparing registration...

TESTIMONIALS

Agenda Preview

You can download our latest agenda here.

Download the 2021 agenda now. Simply fill in this form and we'll send you a PDF version immediately. We need some information to know where to send the file and how to address our email to you.

 

Download 2021 Agenda

WHO WILL BE THERE

Network with industry experts from:

  • Big pharma and biotech
  • Cell Therapy Academics and clinicians 
  • Process standardisation - technology/services
  • Logistics companies - cell storage/transport
  • Service providers - CRO’s, Consultants, Government

Past attendees include:

Resources

Download Resource

Returning Safely Measures

Whether sponsors, speakers or attendees, our customers attend Kisaco Research events to connect, learn and innovate to know more and do business. It is our commitment that as we return to in-person events, they can do this effectively, safely and with confidence.

All in-person Kisaco Research events will prioritize the health and safety of colleagues and customers and, in the first instance, will be run in accordance with official government and local authority guidance, as well as any venue or location-specific regulations.

Kisaco Research is committed to following the Association of Event Organisers All Secure Standard, which has been approved by by UK Government.

Download the Kisaco Research Returning Safely Measures 

About Kisaco Research

Kisaco Research produces, designs and hosts B2B industry conferences, exhibitions and communities – focused on a specialized selection of topic areas.

Meet industry peers that will help build a career-changing network for life.

Learn from the mistakes of your peers as much as their successes—ambitious industry stalwarts who are happy to share not just what has made them successful so far but also their plans for future proofing their companies.

Note down the inspired insight that will form the foundation for future strategies and roadmaps, both at our events and through our online communities.

Invest both in your company growth and your own personal development by signing up to one of our events and get started.

Contact Us